< em > NF1 < /em > -Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of < em > NF1 < /em > -Mutant Rhabdomyosarcoma and < em > NF1 < /em > -Associated Malignant Triton Tumor

CONCLUSION: Patients with NF1-mutant ERMS lacking TP53 alterations may benefit from dose-reduction chemotherapy. On the basis of the diagnostic challenges and significant treatment and prognostic differences, molecular profiling of challenging tumors with rhabdomyoblastic differentiation is recommended.PMID:38603649 | DOI:10.1200/PO.23.00597

Source: Cancer Control - April 11, 2024 Category: Cancer & Oncology Authors: Henry de Traux de Wardin Josephine K Dermawan Fabio Vanoli Samuel C Jiang Samuel Singer Ping Chi William Tap Leonard H Wexler Cristina R Antonescu Source Type: research